Viking Therapeutics SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 28, 2026, 4:10 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedViking Therapeutics Q3 2026 GAAP net loss per share of $1.55 widens from $0.81 and misses $1.06 consensus; cash rises to $960 million after offerings
8-KSept. 28, 2026, 5:27 p.m. ETView on SEC.gov
Entry into a material definitive agreement · Creation of a direct financial obligation · Financial statements and exhibits
424B5Sept. 24, 2026, 9:05 p.m. ETView on SEC.gov
424B5Sept. 24, 2026, 9:04 p.m. ETView on SEC.gov
424B5Sept. 23, 2026, 5:13 p.m. ETView on SEC.gov
424B5Sept. 23, 2026, 5:13 p.m. ETView on SEC.gov
8-KSept. 22, 2026, 7:06 a.m. ETView on SEC.gov
Other events · Financial statements and exhibits
4Aug. 7, 2026, 4:34 p.m. ETView on SEC.gov
4July 29, 2026, 8:07 p.m. ETView on SEC.gov
4July 29, 2026, 8:06 p.m. ETView on SEC.gov
4July 29, 2026, 8:06 p.m. ETView on SEC.gov
10-QJuly 29, 2026, 5:15 p.m. ETView on SEC.gov
8-KJuly 29, 2026, 4:05 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits